The Kowalinski group at EMBL Grenoble discovered notable differences between the nuclear cap-binding complex in trypanosomes and humans, a critical component in cellular RNA metabolism. Trypanosomes ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

A new study from the Kowalinski group at EMBL Grenoble characterized the structure of an important trypanosomal protein ...

Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, ...

DYNE-101 eased myotonia and led to other functional improvements for people with myotonic dystrophy type 1 (DM1) in a ...

Earlier this week, the American Cancer Society released the full list of 245 new and renewed research grants that were ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, ...

Scientists at the University of California, Irvine, have discovered that nuclear speckles, a membraneless organelle within ...

Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.

Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder ...